Association. Innovation in Medicines PDA: A Global. and Manufacturing. David Tainsh, GSK Keith Pugh, MHRA
|
|
- David Hodges
- 5 years ago
- Views:
Transcription
1 Innovation in Medicines PDA: A Global and Manufacturing Association David Tainsh, GSK Keith Pugh, MHRA Joint Regulators/Industry QbD Workshop January 2014 London, UK
2 Introduction Current State We have heard a lot about the challenges and successes of applying QbD Aside from Biopharms which we know are complex, Immediate Release Products are just the tip of the iceberg and we need to be more innovative if we are to be successful in delivering consistent and reliable quality for all products. Future State So before we close this workshop we just wanted to reflect on some of the new challenges facing us, what could be different and to ask how do you see it? 2
3 Challenges to Innovation Current Levels of Technical Capability Availability of New Skillsets Unwillingness to Deploy New Technology Large Investment in the Current State Perceptions of High Regulatory Hurdles Lack of Process to Manage Complex LCM Changes Lack of an Overall Vision on How to Modernise Pharmaceutical Manufacture 3
4 Opportunities for Innovation Novel Product Types for QbD More Complex Traditional Medicines Prolonged release Oral, Inhaled DPI, Nanoparticulates Novel products Advanced Therapeutics, Oligonucleotides, Microneedles Novel Methods of Manufacture & Control Continuous Synthetic Biochemistry - Biotransformations Discrete Manufacture & Novel Analytics Others? 4
5 Continuous Manufacturing: - Enabling Things Batch Can t Do Benefitting - Quality for Patients, - Environment - Business Process Shorter End to End Process Times Faster, Lower Cost Development More Process Understanding Factory Lower Work In Progress Costs Safer More Scale Independent Business Reliable Consistency Volume Flexibility Sustainable & Greener
6 Synthetic Biochemistry Moving to Microbial Cell Factories Greener, Cleaner, Cheaper - No solvents, fewer reagents - Fewer isolations & by-products - Aqueous based benign waste Biotransformations can be very specific in terms of chirality, position and functional group. Chemoenzymatic Approach Cascade Synthesis Enzyme Enzyme
7 Liquid Dispensing Technology Platform Industrial scale machine installed to provide Phase 3 and Launch Capability Capacity: 1 million tablets/day, upgradable to 2 million/day 7
8 Manufacturing - A Paradigm Shift Mfg.. Batch Mfg.. Discrete Units Population of Many Quality assessed by sampling post manufacture Population of One Quality assessed on-line for every tablet 8
9 Liquid Dispensing Technology with PAT UV / NIR [suspension concentration] 1. Vision system, droplet size 2. Droplet weight 1. Image analysis 2. NIR Chemical Imaging IR or Microwave Drug Solution or Suspension + Placebo Tablets Low Volume (c. 2-20ul) Dispensing Drying On-Line Analysis Chemical Imaging Surface Coating & Printing No Linkage between First and Last Tablet 9
10 Process Analytical Technologies Video Image of Droplet: What was Delivered NIR Chemical Imaging: Where on the Tablet 10
11 Comparison of Droplet Content Uniformity vs Typical 2mg Tablet Content Uniformity LSL -3.s +3.s USL E E E6 7E6 7.02E6 7.04E6 7.06E6 7.08E6 7.1E6 7.12E6 7.14E6 7.16E6 7.18E6 7.2E6 7.22E6 7.24E6 7.26E6 7.28E6 7.3E6 7.32E6 7.34E6 7.36E6 Frequency 11 85% Droplet N= 606 PpK =16 115% LSL -3.*S Nominal +3.*S USL Tablet N= 520 PpK =
12 100% Vision QC Inspection Control and Testing UV Solution Analysis Reticule Calibration Drop Volume/Dose Content Tunnel Temp. Conditions NIR Dose Position Inspection 100% Vision QC Inspection Incoming core tablet Dosing Drying Coating & Printing Wet Dose Position Inspection Droplet Weight Check Pad Inspection/ Coating Confirmation 12 System monitoring tablet shift register and rejection confirmation
13 Desired State A Vision to Modernise Pharmaceutical Manufacture Enabling Regulatory Strategy and Process that keeps pace with Innovation Increased Opportunities for Scientific Dialogue around innovative platforms Education and Training to Provide New Skillsets Enhanced scientific and risk based approaches to QbD to match new technologies A Simplified and Streamlined Variations Process 13
14 Challenges to Innovation Current Levels of Technical Capability Availability of New Skillsets Unwillingness to Deploy New Technology Large Investment in the Current State Perceptions of High Regulatory Hurdles Lack of Process to Manage Complex LCM Changes Lack of an Overall Vision on How to Modernise Pharmaceutical Manufacture 14
15 Desired State A Vision to Modernise Pharmaceutical Manufacture - Industry driven Enabling Regulatory Strategy and Process that keeps pace with Innovation Facilitate within existing Regulation 15
16 Desired State Increased Opportunities for Scientific Dialogue around innovative platforms - Scientific Advice (EMA/NCA) - Working Parties e.g. QWP, BWP - PAT team - early interactions recommended Education and Training to Provide New Skillsets - Should also include Regulators 16
17 Desired State Enhanced scientific and risk based approaches to QbD to match new technologies - Apply and build on existing learning A Simplified and Streamlined Variations Process - EU legislation (Common system since August 2013) - Changes already classified on a risk based basis - Detailed classification guideline 17
18 Summary - Types of Variations Changes not requiring any prior approval Changes requiring prior approval Design Space No submission required if within an approved design space Type IA Do & tell Type IB (Default) Tell, wait & do Variations Type II Extension Evaluation Procedure adapted to the level of risk
19 Desired State A Simplified and Streamlined Variations Process - EU - Changes already classified on a risk based basis - Additional flexibility Post Approval Change Management Protocol (PACMP) - justify downgrading in type of required variation - no restrictions to the nature of changes - limit (Type IB) regarding level of downgrading for biopharmaceutical products. - Global challenges - What do you want? 19
20 Conclusion By No Means a Comprehensive View of the Challenges Facing All of Us or the Possible Solutions But a Stimulus for Further Discussion So How do you See the future Challenges and Opportunities for Innovation? 20
GSK s Development of Novel Oral Delivery Technologies Perspectives
GSK s Development of Novel Oral Delivery Technologies Perspectives Mark Wilson Director, PTS, R&D GlaxoSmithKline Pharmaceuticals GSK Established a Technology Incubator To Develop Drug Delivery Systems
More informationQ8 and Q8 annex An industry Perspective
Workshop on Implementation of ICH Q8/Q9/Q10 and Other Quality Guidelines Beijing December 2008 Q8 and Q8 annex An industry Perspective Brian Withers, Abbott Laboratories, United Kingdom I attend this conference
More informationChallenges of Implementation of ICH Q 8
Challenges of Implementation of ICH Q 8 A Regulatory Perspective Dr. Susanne Keitel BioKorea, Seoul, September 2007 Overview of the Presentation ICH Q 8: Background; EU Experience Design Space Associated
More informationFeedback EMEA / Industry Discussion
Feedback EMEA / Industry Discussion Eli Lilly & Co Ltd Case Study: Use of In-Line Near-Infrared Spectroscopy to Monitor Segregation of a Pharmaceutical Powder Blend in a Tablet Press Martin Diller PhD,
More informationAnalytical Methods and Sampling in the New Manufacturing Paradigm a Regulatory Perspective
Analytical Methods and Sampling in the New Manufacturing Paradigm a Regulatory Perspective Dr. Øyvind Holte Norwegian Medicines Agency EMA PAT team/ EDQM PAT working party 15 October, 2014, Heidelberg
More informationQuality by Design and OINDP. Today s Presentation
Quality by Design and OINDP Setting the Stage John C Berridge IPAC-RS September 2008 Today s Presentation QbD definition Setting the stage from an ICH perspective Future Opportunities 2 QbD Definition
More informationEU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson
EU GMP Evolution or Revolution Scope and drivers for EU GMP changes August 2015 Gordon Farquharson EU & PIC/S Harmonisation at IWG level now Slide 2 PharmOut 2015 EU & PIC/S Harmonisation (1) What does
More informationCMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D.
CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D. Senior Scientist (for Quality) Pharmaceuticals and Medical Devices Agency (PMDA) MFDS Nov 11, 2016 1 Agenda Introduction of PMDA ICH Q12 QbD assessment
More informationSTRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN
STRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN CHRISTOPHER J POTTER ISPE ADVISOR AND CMC CONSULTANT 1 AGENDA Background ICH Guidelines Terms and Definitions Supporting Information ISPE publications
More informationWorkshop Guide. Joint Regulators/Industry QbD Workshop January 2014 London, UK. europe.pda.org/ema2014
EMA together with other EU Health Agencies Joint Regulators/Industry QbD Workshop 28-29 January 2014 London, UK Workshop Guide europe.pda.org/ema2014 ORGANIZED BY PDA EUROPE Letter from the Chairs Dear
More informationPMDA perspective on Quality by Design for pharmaceutical products
PMDA perspective on Quality by Design for pharmaceutical products Junichi Fukuchi, Ph.D. Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices Agency (PMDA) Annual conference
More informationpeace of mind For from development to commercial supply
For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number
More informationClaus Mortensen, Medicines Inspector. Danish Medicines Agency. Member of the EMEA PAT team
Claus Mortensen, Medicines Inspector Danish Medicines Agency Member of the EMEA PAT team EMEA progress and status what is needed to document scientific understanding in a PAT application EMEA PAT team
More informationQuality by Design, Clinical Relevance & Lifecycle Considerations
Quality by Design, Clinical Relevance & Lifecycle Considerations Robert Iser Acting Director Office of Process & Facilities / OPQ / CDER IFPAC 2016 1 FDA Quality Related Guidance and Initiatives Initiatives
More informationICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
14 th DIA Japan Annual Meeting 2017 November 12-14, 2017 Tokyo Big Sight Ariake ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal Reviewer Office
More informationTerrence Tougas. Dennis Sandell
Terrence Tougas Boehringer Ingeheim, Ridgefield, CT Dennis Sandell S5 Consulting, Lund, Sweden (c) 2011 Sandell & Tougas 1 Transforming the general concept of Quality into objective, well defined and actionable
More informationPharmaceutical Manufacturing and Engineering Catalog Excerpt
Pharmaceutical Manufacturing and Engineering Catalog Excerpt PME 530 Introduction to Pharmaceutical Manufacturing Pharmaceutical manufacturing is vital to the success of the technical operations of a pharmaceutical
More informationThe Changing Face of Product and Process Development in the QbD Era. James Kraunsoe AstraZeneca Product Development UK/US
The Changing Face of Product and Process Development in the QbD Era James Kraunsoe AstraZeneca Product Development UK/US Disclaimer The views and opinions expressed in the following PowerPoint slides are
More informationForeign Particulate Matter testing using the Morphologi G3
Foreign Particulate Matter testing using the Morphologi G3 Introduction The Morphologi G3 with its Foreign Particle Detection capabilities allows the detection, enumeration and size classification of foreign
More informationInter-Association Task Force
Inter-Association Task Force Presentation to EMA Workshop Prevention of Drug Shortages Based on Quality and Manufacturing Issues 9 th October 2015 1 Topics for Today Background and history of task force
More informationReflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation
Reflection Paper on synergies between regulatory and HTA issues DG SANTE Unit B4 Medical products: safety, quality, innovation STAMP meeting, 28 June 2016 Outline Aim of the Reflection Paper Drafting process
More informationValue Paper. Are you PAT and QbD Ready? Get up to speed
Value Paper Are you PAT and QbD Ready? Get up to speed PAT and Quality-by-Design As PAT and Quality -by-design (QbD) become an integral part of the regulatory framework, automation group ABB argues more
More informationConsiGma TM, a platform for continuous processing
ConsiGma TM, a platform for continuous processing GEA Pharma Systems Where Inspiration meets Technology GEA Process Engineering / GEA Pharma Systems ConsiGma TM R&D and Manufacturing platform ConsiGma
More information25 th Workshop of the EURORDIS Round Table of Companies (ERTC)
25 th Workshop of the EURORDIS Round Table of Companies (ERTC) Healthcare Companies & European Reference Networks: Expectations & Potential for Collaboration Introduction Tuesday 26 September, 2017 (09:00
More informationSTOA Workshop. New technologies and Regional Policy Towards the next Cohesion Policy framework. Industrial policy and investments for growth
STOA Workshop New technologies and Regional Policy Towards the next Cohesion Policy framework Industrial policy and investments for growth Brussels, 16 October 2017 Dana Eleftheriadou Policy Coordinator
More informationImpact of ICH Q9 and the application of Risk Management
Safeguarding public health Impact of ICH Q9 and the application of Risk Management An inspector s perspective on the impact on inspectional approaches and expectations Ian Thrussell Strategy and Development
More informationLeader in Pharmaceutical Films
TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Films Your Specialist in Contract Development & Manufacturing WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation
More informationOffice of Pharmaceutical Quality Key Quality Initiatives
Office of Pharmaceutical Quality Key Quality Initiatives Ashley B. Boam, MSBE Director Office of Policy for Pharmaceutical Quality Office of Pharmaceutical Quality Center for Drug Evaluation and Research
More informationIndustrial Innovation Information Days Brussels 3-4 October 2017
Industrial Innovation Information Days Brussels 3-4 October 2017 NMBP Programme Parallel Sessions OPEN INNOVATION TEST BEDS Calls 2018/2019 Helene CHRAYE, HoU Unit D3 DG Research & Innovation A joint presentation
More informationPharmaceutical Process Development
Announcing the following Seminar to be conducted by IVEPE-SEV Pharmaceutical Process Development Factors in Scale-Up, Process Validation and Regulatory Considerations Course Topics Include: Solid Dosage
More informationProgress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003
Progress in FDA s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003 Impetus for Initiative: Modernization and continuous improvement in pharmaceutical manufacturing sector slow compared
More informationUpdate on Lessons Learned from the EMA-FDA QbD Pilot
Update on Lessons Learned from the EMA-FDA QbD Pilot IFPAC 2014 Annual Meeting 22 January 2014 Sharmista Chatterjee, Ph.D. CMC Lead for QbD, ONDQA/OPS/CDER/FDA Background One of the projected outcomes
More informationthe SPD company Dr Clive Simon, Principal, The SPD Company.
the SPD company With decades of local and international experience at the coalface, The SPD Company s specialists have built a solid repertoire of in-depth technical knowledge within the highly-regulated
More informationEDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality
EDQM Conference Quality of Medicines in a Globalised World: Dreams and Reality 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Plenary Session Dr Moheb M. Nasr
More informationImportance of ICH Guidance in Fulfilling Process Validation Requirements
Importance of ICH Guidance in Fulfilling Process Validation Requirements Presented by: Gamal Amer All rights reserved. Do not copy without permission. Principal 1 Premier Compliance Services, Inc. Process
More informationFT-IR.
FT-IR varian, inc. 610/620-IR ft-ir MICROSCOPY AND IMAGING SoLUTIONS www.varianinc.com VARIAN, INC. Setting the Standard Again When Only the Best Will Do The world leader in molecular spectroscopy innovation
More informationRequirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, Dr. Helmut Rockstroh
Requirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, 2015 Dr. Helmut Rockstroh Overview Introduction - Scope Pharmacopoeial + HA Positions Examples / Case Studies Discussion 2 Introduction:
More informationProgressive Licensing and the Modernization of the Canadian Regulatory Framework
Progressive Licensing and the Modernization of the Canadian Regulatory Framework Workshop on Implementation of ICH Quality Guidelines Beijing, China 3-5 December, 2008 Mike Ward Health Canada 1 DISCLAIMER
More informationThe Effect of Coating Process Conditions and Coating Formula Type on the Quantity and Location of Water in Film Coated Tablets
OPADRY II Application Data High Performance Film Coating System The Effect of Coating Process Conditions and Coating Formula Type on the Quantity and Location of Water in Film Coated Tablets OBJECTIVES
More informationEDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality
EDQM Conference Quality of Medicines in a Globalised World: Dreams and Reality 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Dr Georges France Ms Suzette Kox
More informationPDA 71 Years of Connecting People, Science and Regulation
PDA 71 Years of Connecting People, Science and Regulation 1 I m happy to be here. Bom Dia. Estou feliz por estar aqui. Richard M. Johnson PDA President & CEO since 2009 38 years experience in US and International
More informationQuality by Design. Innovate Design Development Create value. Correct definition of QbD and its relation to product and process development
Innovate Development Create value Quality by Correct definition of QbD and its relation to product and process development Dr John Loveluck 42 Technology Ltd +44 1480 302700 john.loveluck@42technology.com
More informationHealth & Social Care Industrial Innovation
Health & Social Care Industrial Innovation Mr Andrew Fowlie Scottish Government Health Innovations Team SHINE North Sea Region Program 2014 2020 Scotland s Medical Technologies Landscape Imaging Non Imaging
More informationTECHNOLOGY TRANSFER:
TECHNOLOGY TRANSFER: AN INTERNATIONAL GOOD PRACTICE GUIDE FOR PHARMACEUTICALS AND ALLIED INDUSTRIES Mark Gibson Editor PDA Bethesda, MD, USA DHI Publishing, LLC River Grove, IL, USA 10 9 8 7 6 5 4 3 2
More informationImportance of SMEs in Greening the Economy in Georgia
Importance of SMEs in Greening the Economy in Georgia EaP Green Ministry of Environment and Natural Resources Protection of Georgia February 12, 2015 Kiev, Ukraine Importance of Green Economy for Georgia
More informationInnovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series
CAMO European Pharmaceutical Seminars Jan/Feb 2009 Innovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series The Increasing Need of Multivariate Analysis for Process Understanding
More informationEDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS
EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE 1992-2012: 20 YEARS OF EXPERIENCE 22-23 March 2012 EDQM, Strasbourg, France ABSTRACTS PLENARY SESSION, 22 March 2012 ABSTRACT 1.3 The Evolution
More informationCDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals
CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals Lawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration IFPAC
More informationAPX TM TWO-WAY RADIOS NORTH AMERICA REGION. MotorolaSolutions.com/Services
APX TM TWO-WAY RADIOS NORTH AMERICA REGION MotorolaSolutions.com/Services PREMIER SERVICES MAXIMIZE PERFORMANCE AND REDUCE RISK The task of maintaining and supporting a large inventory of two-way radios
More informationThe Process Analytical Technology Initiative: PAT and the Pharmacopeias
The Process Analytical Technology Initiative: PAT and the Pharmacopeias Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science CDER, FDA EDQM Spring Conference, Cannes, 3-43 4 May 2004
More informationImplementing Quality Systems
Implementing Quality Systems CGMP By The Sea August 29, 2006 Chris Joneckis, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Add FDA Bar and Presentation Overview Driving
More informationIMI Revolutionising Europe s Pharmaceutical Industry. IMI Matters!
IMI Revolutionising Europe s Pharmaceutical Industry IMI Matters! Session in the Framework of the Event Joint Technology Initiatives Innovation in Action 4 6 October 2011 European Parliament Brussels Programme
More informationMastering Environmental Monitoring
pda.org/eu/em2019 2019 PDA EUROPE TRAINING Mastering Environmental Monitoring 15-16 OCTOBER 2019 WATTWIL, SWITZERLAND CONNECTING PEOPLE SCIENCE AND REGULATION Training & Education Program europe.pda.org
More informationConvergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA
EUnetHTA European network for Health Technology Assessment Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA University of Tokyo, October 24,
More informationFuture of Pharmaceutical Quality and the Path to Get There
Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research INTERPHEX 2018, April 18, 2018,
More informationCPC Essentials I Part A Introduction to CPC Essentials and Patent Classification Systems
CPC Essentials I Part A Introduction to CPC Essentials and Patent Classification Systems Classification Quality and International Cooperation (CQIC) Division Office of International Patent Cooperation
More informationICH Q8, 9 & 10 and the Impact on the QP
1 ICH Q8, 9 & 10 and the Impact on the QP Peter H. Gough David Begg Associates phg@david-begg-associates.com 2 A New Approach to Regulation Approach to the regulation of pharmaceuticals is undergoing a
More informationBiomedical Innovation Has Science Overtaken the System?
Adaptive Pathways for Transformative Medicinal Products. A New Paradigm with the Enhanced Application of Real-World Evidence? ISPOR 20 th Annual European Congress, Glasgow, Scotland Issue Panel 21, Wednesday,
More informationOur position. ICDPPC declaration on ethics and data protection in artificial intelligence
ICDPPC declaration on ethics and data protection in artificial intelligence AmCham EU speaks for American companies committed to Europe on trade, investment and competitiveness issues. It aims to ensure
More informationThe Power of Print in Laminated Card Manufacturing
The Power of Print in Laminated Card Manufacturing ICMA EuroForum 2014-9 th / 10 th October Robin McMillan & John Schneiderhan working for you. Overview Current print processes and related inks Introduction
More informationSection heading. Strapline sub-heading
Section heading Strapline sub-heading Smart every time NextPharma stands out as your pharmaceutical development and manufacturing partner with fast, flexible and tailored solutions for markets worldwide
More informationSpectrum 400. FT-IR and FT-NIR Spectrometer. There is only one answer.
Spectrum 400 FT-IR and FT-NIR Spectrometer There is only one answer. The latest innovation in PerkinElmer s long history of IR technology leadership For over 60 years, PerkinElmer has been the world leader
More informationMastering Environmental Monitoring
pda.org/eu/em2019 2019 PDA EUROPE TRAINING Mastering Environmental Monitoring 15-16 OCTOBER 2019 WATTWIL, SWITZERLAND CONNECTING PEOPLE SCIENCE AND REGULATION Training & Education Program europe.pda.org
More informationSymposium on Continuous Manufacturing of Pharmaceuticals Notes
1 2012 11 13 Symposium on Continuous Manufacturing of Pharmaceuticals Notes These are notes from the first open meeting regarding Novartis- MIT Center for Continuous Manufacturing (CCM). The meeting is
More informationEnpr EMA. Enpr-EMA. European Network of Paediatric Research at the European Medicines Agency
Enpr EMA European Network of Paediatric Research at the European Medicines Agency Enpr-EMA European Network of Paediatric Research at the European Medicines Agency An agency of the European Union Enpr
More informationNear-IR cameras... R&D and Industrial Applications
R&D and Industrial Applications 1 Near-IR cameras... R&D and Industrial Applications José Bretes (FLIR Advanced Thermal Solutions) jose.bretes@flir.fr / +33 1 60 37 80 82 ABSTRACT. Human eye is sensitive
More informationTraining. Education CALENDAR FEDEGARI TECH CENTERS DM#407036
2016 CALENDAR COLLABORATION IN THE LIFE SCIENCES WORLD Valued customer, The need to increase efficiency and reliability in pharmaceutical manufacturing presents firms with unique opportunities to develop
More informationFrom API to Formulated Product
From API to Formulated Product Jean-Marie Geoffroy, PhD Director, Product Development Takeda Global Research & Development 675 N Field Drive Lake Forest, IL 60045 jean-marie.geoffroy@tgrd.com Acknowledgments
More informationHow Process Models can Facilitate Quality Risk Management for Emerging Technologies
How Process Models can Facilitate Quality Risk Management for Emerging Technologies Thomas O Connor, Ph.D. FDA-AIChE Workshop on Adopting Continuous Manufacturing North Bethesda, MD March 2 th, 2016 2
More informationKEY HIGHLIGHTS WORKSHOP 2019
KEY HIGHLIGHTS aenvironmental Monitoring afacility Design apractical Case Studies avisual Inspection aclean Room Behaviours aprocess Simulations arecent 483s, warning Letters and EU Observations WORKSHOP
More informationMEDIA RELEASE FOR IMMEDIATE RELEASE 4 JUNE 2014
MEDIA RELEASE FOR IMMEDIATE RELEASE 4 JUNE 2014 A*STAR-HELLMA PARTNERSHIP TO INNOVATE MANUFACTURING PROCESSES Hellma Analytics, a leading company in optics analysis technologies, partners with A*STAR to
More informationCEOCFO Magazine. Pat Patterson, CPT President and Founder. Agilis Consulting Group, LLC
CEOCFO Magazine ceocfointerviews.com All rights reserved! Issue: July 10, 2017 Human Factors Firm helping Medical Device and Pharmaceutical Companies Ensure Usability, Safety, Instructions and Training
More informationSupporting Innovation through Regulation and Science
Supporting Innovation through Regulation and Science Larry O Dwyer, Scientific Affairs Manager PEARRL Regulatory Science Symposium 21 st June 2017, School of Pharmacy, UCC Overview of Presentation Drivers
More informationLundbeck s view on the EU IP systems
Lundbeck s view on the EU IP systems Forårsmøde IPR in the EU May 26 2011 H. Lundbeck A/S 1 Agenda The Innovative Pharmaceutical Industry and why IP is so important for Lundbeck Lundbeck s wish list for
More informationIGDRP Mission, Scope, How it works
IGDRP Mission, Scope, How it works IGDRP-EDQM Workshop Strasbourg, France 13 May 2016 Dr. Craig Simon Associate Director, Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada
More informationASEPTIC PROCESSING, TODAY AND FUTURE
ASEPTIC PROCESSING, TODAY AND FUTURE Dublin, Ireland, 4 October 2018 Marco Delgado Rueda ALL RIGHTS RESERVED 2018 PAREXEL INTERNATIONAL CORP. AGENDA Today s Reality and Needs Issues and Probable Causes
More informationEU s Innovative Medical Technology and EMA s Measures
EU s Innovative Medical Technology and EMA s Measures 27 October 2017 Summit symposium 25-27 October 2017, Kyoto, Japan Presented by Guido Rasi Executive Director, European Medicines Agency (EMA) An agency
More informationUSP Research & Innovation Program
USP Research & Innovation Program Ding Ming, Ph.D. Vice president, Research & Innovation United States Pharmacopeial Convention (USP) October 13, 2016 USP Programs and Products Impact Millions Worldwide
More informationAndalusian Agency for Health Technology Assessment (AETSA)
Andalusian Agency for Health Technology Assessment (AETSA) Seville, 22 nd of July, 2016 Comments on the concept paper Facilitating the translation of advanced therapies to patients in Europe 1 Introduction
More informationMedicines Manufacturing in the UK 2017
Medicines Manufacturing in the UK 2017 Moderator: Magda Papadaki, PhD Head of Manufacturing Innovation The Association of the British Pharmaceutical Industry Medicines Manufacturing Industry Partnership
More informationPeter Gregory Managing Director, Publishing Royal Society of Chemistry
Society Publishing and Open Access Peter Gregory Managing Director, Publishing Royal Society of Chemistry My Background Ph.D. Chemist Post-doc research in Germany Ca. 20 papers published Associate Editor
More informationFDA s Evolving Approach to Pharmaceutical Quality
FDA s Evolving Approach to Pharmaceutical Quality Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research 10th Annual FDA Inspections Summit Nov.
More informationRecent Trend of Generic Medicines Market In Japan
Recent Trend of Generic Medicines Market In Japan Joint 22 nd EGA and 19 th IGBA Annual Conference Dubrovnik, Croatia 9 June, 2016 Itsuro Yoshida President of Japan Generic Medicines Association Copyright
More informationMeasurement & Control Technology
Measurement & Control Technology For process and laboratory analysis s Material properties s Colour measurement s Radiation measurement s Moisture measurement (NIR, microwave & RF) s Refractometers M.C.
More informationABOUT THE MINISTERIAL PROGRAMME
Official Sponsor 1 2 ABOUT THE MINISTERIAL PROGRAMME The Ministerial Programme at Mobile World Congress is an influential forum offering senior government representatives an opportunity to expand their
More informationPharmaceutical Patents and Evergreening. Jürgen Dressel Head of Global Patent Litigation Strategy, Novartis Pharma FICPI 2015, Cape Town, 14 Apr 2015
Pharmaceutical Patents and Evergreening Jürgen Dressel Head of Global Patent Litigation Strategy, Novartis Pharma FICPI 2015, Cape Town, 14 Apr 2015 Originator My personal views 2 Pharmaceutical Patents
More informationSubmission of comments on Review of the Variations Guidelines (EC 1234/2008)
12 July 2012 Submission of comments on Review of the Variations Guidelines (EC 1234/2008) Comments from: Name of organisation or individual Leem Please note that these comments and the identity of the
More informationProcess Analytical Technology (PAT): A Real Time Quality Assurance
Review Article Process Analytical Technology (PAT): A Real Time Quality Assurance Punita Raj, N. Vishal Gupta* Pharmaceutical Quality Assurance group, JSS College of Pharmacy, JSS University, Sri Shivarathreeshwara
More informationModel Based Design Of Medical Devices
Model Based Design Of Medical Devices A Tata Elxsi Perspective Tata Elxsi s Solutions - Medical Electronics Abstract Modeling and Simulation (M&S) is an important tool that may be employed in the end-to-end
More informationDecision regarding PHARMAC s Implementation of Trans-Pacific Partnership (TPP) provisions and other Amendments to Application Processes
8 December 2016 Decision regarding PHARMAC s Implementation of Trans-Pacific Partnership (TPP) provisions and other Amendments to Application Processes PHARMAC is pleased to announce that changes will
More informationHealth Care Ltd 3M United Kingdom PLC Every day, 3M people find new ways to make amazing things happen. Wherever they are, whatever they do, the company s customers know they can rely on 3M to help make
More informationChallenges, benefits, case study
hallenges, benefits, case study Pharmaceutical development phases overview The new paradigm for development: Quality by Design (QbD) hallenges Benefits ase study losure and Q&A»»»»»» D. eriani Meet MINITAB,
More information18th World Conference on Non-destructive Testing, April 2012, Durban, South Africa
18th World Conference on Non-destructive Testing, 16-20 April 20, Durban, South Africa Guided Wave Testing for touch point corrosion David ALLEYNE Guided Ultrasonics Ltd, London, UK; Phone: +44 2082329102;
More informationInstitute of Physical and Chemical Research Flowcharts for Achieving Mid to Long-term Objectives
Document 3-4 Institute of Physical and Chemical Research Flowcharts for Achieving Mid to Long-term Objectives Basic Research Promotion Division : Expected outcome : Output : Approach 1 3.1 Establishment
More informationThe New Delhi Communiqué
India-EU Ministerial Science Conference 7-8 February 2007, New Delhi The New Delhi Communiqué BACKGROUND TO CONFERENCE At their Summit in Helsinki in October 2006, the leaders of the EU and India reiterated
More informationNHS Next Stage Review: Innovation
NHS Next Stage Review: Innovation January 2008 Introduction 1. The Academy of Medical Sciences welcomes the opportunity to contribute to the NHS Next Stage Review. In this short response we have focused
More informationThe future of work. Artificial Intelligence series
The future of work Artificial Intelligence series The future of work March 2017 02 Cognition and the future of work We live in an era of unprecedented change. The world s population is expected to reach
More informationVisioNIR. High Speed NIR Spectrometer for 100% Process Inspection
VisioNIR High Speed NIR Spectrometer for 100% Process Inspection Table of Content Introduction... 2 visiotec VisioNIR High Speed NIR Spectrometer: Your Way to PAT... 2 The benefits of the VisioNIR system...
More informationUltrasensitive LC MS/MS: Agilent 6470 and 6495 LC-QQQ
Ultrasensitive LC MS/MS: Agilent 6470 and 6495 LC-QQQ ROCK SOLID Performance for Trace-Level Quantitation Agilent Technologies 1 Brief History of Agilent 6400 QQQ LC/MS 6410 2006 6460 Agilent Jet Stream
More informationSECOND GLOBAL SYMPOSIUM ON HEALTH SYSTEMS RESEARCH SCIENCE TO ACCELERATE UNIVERSAL HEALTH COVERAGE
SECOND GLOBAL SYMPOSIUM ON HEALTH SYSTEMS RESEARCH SCIENCE TO ACCELERATE UNIVERSAL HEALTH COVERAGE Beijing, 31 October - 3 November 2012 Background The Second Global Symposium on Health Systems Research
More information